Non-reducing end unsaturated mannuronic acid oligosaccharides and compositions containing same as active ingredient
View Patent ↗Disclosed is a non-reducing end unsaturated mannuronic acid oligosaccharide having a molecular weight of 100-3000 Da, which is obtained by lysing polymannuronate as a substrate with alginate lyase, and provided are: a non-reducing end unsaturated mannuronic acid oligosaccharide; and pharmaceutical compositions for alleviating, preventing, or treating obesity, diabetes, and climacteric syndrome, and probiotics for promoting intestinal beneficial bacteria, the compositions and probiotics containing, as an active ingredient, the non-reducing end unsaturated mannuronic acid oligosaccharide, so that the antiobesity and antidiabetic effects, estrogen activity, and intestinal microflora controlling effect of the non-reducing end unsaturated mannuronic acid oligosaccharides are remarkably excellent as compared with non-reducing end saturated mannuronic acid oligosaccharides.
1. A method for alleviating or treating obesity, comprising
administering to a subject in need thereof a composition comprising, a non-reducing end unsaturated alginate oligosaccharide having a molecular weight of 100-3,000 Da, which is obtained by lysing polymannuronate as a substrate with alginate lyase,
wherein the alginate oligosaccharide has a mannuronic acid:quluronic acid ratio of 1.2:1 to 5.0:1.
2. The method of claim 1 , wherein the non-reducing end unsaturated alginate oligosaccharide increases the growth of intestinal bacterial strains.
3. The method of claim 2 , wherein the intestinal bacterial strains are selected from the group consisting of Roseburia sp. and Lactobacillus sp.
4. The method of claim 1 , wherein the composition is a pharmaceutical composition for alleviating or treating obesity, or a food composition or functional food composition for alleviating obesity.
5. A method for alleviating or treating diabetes, comprising
administering to a subject in need thereof a composition comprising a non-reducing end unsaturated alginate oligosaccharide having a molecular weight of 100-3,000 Da, which is obtained by lysing polymannuronate as a substrate with alginate lyase,
wherein the alginate oligosaccharide has a mannuronic acid:quluronic acid ratio of 1.2:1 to 5.0:1.
6. The method of claim 5 , wherein the non-reducing end unsaturated alginate oligosaccharide promotes glucose uptake.
7. The method of claim 5 , wherein the composition is a pharmaceutical composition for alleviating or treating diabetes, or a food composition or functional food composition for alleviating diabetes.
8. A method for alleviating or treating climacteric syndrome, comprising
administering to a subject in need thereof a composition comprising a non-reducing end unsaturated alginate oligosaccharide having a molecular weight of 100-3,000 Da, which is obtained by lysing polymannuronate as a substrate with alginate lyase.
9. The method of claim 8 , wherein the composition further comprises 17β-estradiol.
10. The method of claim 8 , wherein the non-reducing end unsaturated alginate oligosaccharide exhibits a synergic effect together with 17β-estradiol.
11. The method of claim 8 , wherein the composition is a pharmaceutical composition for alleviating or treating climacteric syndrome, or a food composition or functional food composition for alleviating climacteric syndrome.